These findings not only enhance our understanding of the immunosuppressive mechanisms driven by epithelial-derived cancer/testis antigens but also suggest that MAGEA3, MAGEA6, BCL11B, and PAEP may serve as potential biomarkers or therapeutic targets for improving immunotherapy responses in STAD patients. The gene discussed is MAGEA3; the disease is cancer.